Expanded Buprenorphine Access After the 2023 X-Waiver Removal
A rural family physician can now legally prescribe buprenorphine for an established patient without ever holding a DATA-waiver. Whether she should start today turns out to be a different, harder question than whether she’s allowed to.
Dr. E.O. has been W.D.'s physician for nine years, seen every three months for hypertension and type 2 diabetes that have stayed reasonably well controlled thanks largely, in her own read, to how easy she's made it for him to keep showing up. He works at the feed store two miles from her office, in the same small town where she has practiced family medicine for eleven years as the only primary care physician within a thirty-minute drive for roughly four thousand residents. He is forty-five, and until his last visit, his chart had nothing on it resembling this conversation.
He disclosed at that visit that he has been misusing his prescribed tramadol and, more recently, purchasing oxycodone from a family member — an admission he made only after she asked directly why his blood pressure readings had become erratic over the preceding months. He asked her directly, in turn, whether she could help him with buprenorphine rather than referring him an hour away, given how his diabetes management already depends on frequent, easy access to her office. The nearest addiction-specialty clinic has a documented waitlist of several months, and he told her plainly he doubts he'd still be engaged in treatment by the time an appointment came through, given everything else he's already managing. Dr. E.O. has never held a DATA-waiver herself, since obtaining one before 2023 required a dedicated eight-hour training course she never found time for alongside her existing patient load, in a practice where she is often the only clinician in the building. She is now the one asking the practical question — whether the regulatory change she's heard about actually means she can say yes, and what that would really require of her practice if she does.
The waiver is gone. What she still needs is a different question
She can prescribe this today. Section 1262 of the Consolidated Appropriations Act, 2023 removed the federal DATA-waiver requirement entirely, effective immediately under the SAMHSA and DEA guidance issued that January — any practitioner with a standard DEA registration that includes Schedule III authority can prescribe buprenorphine for OUD now. Given her nine-year relationship with this patient and the real hour-plus distance to specialty care, referring him away is a real, not a neutral, choice.
The regulatory change is real, but I want to separate two different things she's asking about: whether she's allowed to prescribe, and whether she's ready to manage induction, dose titration, and complications well. A separate 2023 provision also introduced a one-time eight-hour training requirement on substance use disorders for all controlled-substance prescribers renewing their DEA registration — that training exists precisely because removing the waiver paperwork doesn't remove the clinical learning curve underneath it.
That's a real distinction, but it argues for support during her first cases, not for delaying this specific patient's care until a training module is checked off — the two don't have to be sequential.
Agreed — start him today with a standard buprenorphine induction, and set up a phone consultation with our regional addiction medicine line for this first case specifically, the way several rural practices are already doing. She completes the fuller training on her own schedule rather than making him wait for it.
Agreed: Dr. E.O. starts him on buprenorphine today, with a same-week phone consultation to the regional addiction line for this first induction, and enrolls in the one-time prescriber training on her own schedule.
Not agreed: whether every rural primary care physician newly absorbing this prescribing authority should be required to complete a consultation for their first several inductions, or whether that should remain optional guidance. The psychiatric pharmacist favors a more structured expectation given how new this practice pattern is for many primary care physicians; the addiction medicine specialist worried a formal requirement could itself become a new access barrier in exactly the settings this regulatory change was meant to help.